Molecules and Cells

Korean Society for Molecular and Cellular Biology (한국분자세포생물학회)
권호 표지
DOI QR코드

DOI QR Code

AURKA Suppresses Leukemic THP-1 Cell Differentiation through Inhibition of the KDM6B Pathway

  • Park, Jin Woo (Department of Life Science, College of Natural Sciences, Chung-Ang University) ;
  • Cho, Hana (Department of Life Science, College of Natural Sciences, Chung-Ang University) ;
  • Oh, Hyein (Department of Life Science, College of Natural Sciences, Chung-Ang University) ;
  • Kim, Ji-Young (Department of Life Science, College of Natural Sciences, Chung-Ang University) ;
  • Seo, Sang-Beom (Department of Life Science, College of Natural Sciences, Chung-Ang University)
  • Received : 2017.11.22
  • Accepted : 2018.02.10
  • Published : 2018.05.31
Download PDF
⟨ Previous Next ⟩

Abstract

Aberrations in histone modifications are being studied in mixed-lineage leukemia (MLL)-AF9-driven acute myeloid leukemia (AML). In this study, we focused on the regulation of the differentiation of the MLL-AF9 type AML cell line THP-1. We observed that, upon phorbol 12-myristate 13-acetate (PMA) treatment, THP-1 cells differentiated into monocytes by down-regulating Aurora kinase A (AURKA), resulting in a reduction in H3S10 phosphorylation. We revealed that the AURKA inhibitor alisertib accelerates the expression of the H3K27 demethylase KDM6B, thereby dissociating AURKA and YY1 from the KDM6B promoter region. Using Flow cytometry, we found that alisertib induces THP-1 differentiation into monocytes. Furthermore, we found that treatment with the KDM6B inhibitor GSK-J4 perturbed the PMA-mediated differentiation of THP-1 cells. Thus, we discovered the mechanism of AURKA-KDM6B signaling that controls the differentiation of THP-1 cells, which has implications for biotherapy for leukemia.

Keywords

References

  1. Agger, K., Cloos, P.A., Christensen, J., Pasini, D., Rose, S., Rappsilber, J., Issaeva, I., Canaani, E., Salcini, A.E., and Helin, K. (2007). UTX and JMJD3 are histone H3K27 demethylases involved in HOX gene regulation and development. Nature 449, 731-734. https://doi.org/10.1038/nature06145
  2. Asada, M., Yamada, T., Ichijo, H., Delia, D., Miyazono, K., Fukumuro, K., and Mizutani, S. (1999). Apoptosis inhibitory activity of cytoplasmic p21(Cip1/WAF1) in monocytic differentiation. EMBO J. 18, 1223-1234. https://doi.org/10.1093/emboj/18.5.1223
  3. Auwerx, J. (1991). The human leukemia cell line, THP-1: a multifacetted model for the study of monocyte-macrophage differentiation. Experientia 47, 22-31. https://doi.org/10.1007/BF02041244
  4. Cantu, C., Ierardi, R., Alborelli, I., Fugazza, C., Cassinelli, L., Piconese, S., Bose, F., Ottolenghi, S., Ferrari, G., and Ronchi, A. (2011). Sox6 enhances erythroid differentiation in human erythroid progenitors. Blood 117, 3669-3679. https://doi.org/10.1182/blood-2010-04-282350
  5. Chang, E., Ganguly, S., Rajkhowa, T., Gocke, C.D., Levis, M., and Konig, H. (2016). The combination of FLT3 and DNA methyltransferase inhibition is synergistically cytotoxic to FLT3/ITD acute myeloid leukemia cells. Leukemia 30, 1025-1032. https://doi.org/10.1038/leu.2015.346
  6. Chen, C.W., Koche, R.P., Sinha, A.U., Deshpande, A.J., Zhu, N., Eng, R., Doench, J.G., Xu, H., Chu, S.H., Qi, J., et al. (2015). DOT1L inhibits SIRT1-mediated epigenetic silencing to maintain leukemic gene expression in MLL-rearranged leukemia. Nat. Med. 21, 335-343. https://doi.org/10.1038/nm.3832
  7. Crosio, C., Fimia, G.M., Loury, R., Kimura, M., Okano, Y., Zhou, H., Sen, S., Allis, C.D., and Sassone-Corsi, P. (2002). Mitotic phosphorylation of histone H3: spatio-temporal regulation by mammalian Aurora kinases. Mol. Cell. Biol. 22, 874-885. https://doi.org/10.1128/MCB.22.3.874-885.2002
  8. Daigle, S.R., Olhava, E.J., Therkelsen, C.A., Basavapathruni, A., Jin, L., Boriack-Sjodin, P.A., Allain, C.J., Klaus, C.R., Raimondi, A., Scott, M.P., et al. (2013). Potent inhibition of DOT1L as treatment of MLLfusion leukemia. Blood 122, 1017-1025. https://doi.org/10.1182/blood-2013-04-497644
  9. Fuks, F., Burgers, W.A., Brehm, A., Hughes-Davies, L., and Kouzarides, T. (2000). DNA methyltransferase Dnmt1 associates with histone deacetylase activity. Nat. Genet. 24, 88-91. https://doi.org/10.1038/71750
  10. Gautschi, O., Heighway, J., Mack, P.C., Purnell, P.R., Lara, P.N., Jr., and Gandara, D.R. (2008). Aurora kinases as anticancer drug targets. Clin. Cancer Res. 14, 1639-1648. https://doi.org/10.1158/1078-0432.CCR-07-2179
  11. Gilan, O., Lam, E.Y., Becher, I., Lugo, D., Cannizzaro, E., Joberty, G., Ward, A., Wiese, M., Fong, C.Y., Ftouni, S., et al. (2016). Functional interdependence of BRD4 and DOT1L in MLL leukemia. Nat. Struct. Mol. Biol. 23, 673-681. https://doi.org/10.1038/nsmb.3249
  12. Gorgun, G., Calabrese, E., Hideshima, T., Ecsedy, J., Perrone, G., Mani, M., Ikeda, H., Bianchi, G., Hu, Y., Cirstea, D., et al. (2010). A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma. Blood 115, 5202-5213. https://doi.org/10.1182/blood-2009-12-259523
  13. Gu, J., Gong, Y., Huang, M., Lu, C., Spitz, M.R., and Wu, X. (2007). Polymorphisms of STK15 (Aurora-A) gene and lung cancer risk in Caucasians. Carcinogenesis 28, 350-355.
  14. Han, A., Chae, Y.C., Park, J.W., Kim, K.B., Kim, J.Y., and Seo, S.B. (2015). Transcriptional repression of ANGPT1 by histone H3K9 demethylase KDM3B. BMB Rep. 48, 401-406. https://doi.org/10.5483/BMBRep.2015.48.7.188
  15. Hendzel, M.J., Wei, Y., Mancini, M.A., Van Hooser, A., Ranalli, T., Brinkley, B.R., Bazett-Jones, D.P., and Allis, C.D. (1997). Mitosisspecific phosphorylation of histone H3 initiates primarily within pericentromeric heterochromatin during G2 and spreads in an ordered fashion coincident with mitotic chromosome condensation. Chromosoma 106, 348-360. https://doi.org/10.1007/s004120050256
  16. Hong, S., Cho, Y.W., Yu, L.R., Yu, H., Veenstra, T.D., and Ge, K. (2007). Identification of JmjC domain-containing UTX and JMJD3 as histone H3 lysine 27 demethylases. Proc. Natl. Acad. Sci. USA 104, 18439-18444. https://doi.org/10.1073/pnas.0707292104
  17. Hsu, J.Y., Sun, Z.W., Li, X., Reuben, M., Tatchell, K., Bishop, D.K., Grushcow, J.M., Brame, C.J., Caldwell, J.A., Hunt, D.F., et al. (2000). Mitotic phosphorylation of histone H3 is governed by Ipl1/aurora kinase and Glc7/PP1 phosphatase in budding yeast and nematodes. Cell 102, 279-291. https://doi.org/10.1016/S0092-8674(00)00034-9
  18. Huang, X.F., Luo, S.K., Xu, J., Li, J., Xu, D.R., Wang, L.H., Yan, M., Wang, X.R., Wan, X.B., Zheng, F.M., et al. (2008). Aurora kinase inhibitory VX-680 increases Bax/Bcl-2 ratio and induces apoptosis in Aurora-A-high acute myeloid leukemia. Blood 111, 2854-2865. https://doi.org/10.1182/blood-2007-07-099325
  19. Kim, S.R., Kim, K.B., Chae, Y.C., Park, J.W., and Seo, S.B. (2016). H3S10 phosphorylation-mediated transcriptional regulation by Aurora kinase A. Biochem. Biophys. Res. Commun. 469, 22-28. https://doi.org/10.1016/j.bbrc.2015.11.063
  20. Krivtsov, A.V., and Armstrong, S.A. (2007). MLL translocations, histone modifications and leukaemia stem-cell development. Nat. Rev. Cancer 7, 823-833. https://doi.org/10.1038/nrc2253
  21. Liu, Q., and Ruderman, J.V. (2006). Aurora A, mitotic entry, and spindle bipolarity. Proc. Natl. Acad. Sci. USA 103, 5811-5816. https://doi.org/10.1073/pnas.0601425103
  22. Messeguer, X., Escudero, R., Farre, D., Nunez, O., Martinez, J., and Alba, M.M. (2002). PROMO: detection of known transcription regulatory elements using species-tailored searches. Bioinformatics 18, 333-334. https://doi.org/10.1093/bioinformatics/18.2.333
  23. Meyer, C., Hofmann, J., Burmeister, T., Groger, D., Park, T.S., Emerenciano, M., Pombo de Oliveira, M., Renneville, A., Villarese, P., Macintyre, E., et al. (2013). The MLL recombinome of acute leukemias in 2013. Leukemia 27, 2165-2176. https://doi.org/10.1038/leu.2013.135
  24. Meyer, C., Kowarz, E., Hofmann, J., Renneville, A., Zuna, J., Trka, J., Ben Abdelali, R., Macintyre, E., De Braekeleer, E., De Braekeleer, M., et al. (2009). New insights to the MLL recombinome of acute leukemias. Leukemia 23, 1490-1499. https://doi.org/10.1038/leu.2009.33
  25. Nowak, D., Stewart, D., and Koeffler, H.P. (2009). Differentiation therapy of leukemia: 3 decades of development. Blood 113, 3655-3665. https://doi.org/10.1182/blood-2009-01-198911
  26. Oh, S.T., Kim, K.B., Chae, Y.C., Kang, J.Y., Hahn, Y., and Seo, S.B. (2014). H3K9 histone methyltransferase G9a-mediated transcriptional activation of p21. FEBS Lett. 588, 685-691. https://doi.org/10.1016/j.febslet.2014.01.039
  27. Ota, T., Suto, S., Katayama, H., Han, Z.B., Suzuki, F., Maeda, M., Tanino, M., Terada, Y., and Tatsuka, M. (2002). Increased mitotic phosphorylation of histone H3 attributable to AIM-1/Aurora-B overexpression contributes to chromosome number instability. Cancer Res. 62, 5168-5177.
  28. Plass, C., Oakes, C., Blum, W., and Marcucci, G. (2008). Epigenetics in acute myeloid leukemia. Semin. Oncol. 35, 378-387. https://doi.org/10.1053/j.seminoncol.2008.04.008
  29. Rountree, M.R., Bachman, K.E., and Baylin, S.B. (2000). DNMT1 binds HDAC2 and a new co-repressor, DMAP1, to form a complex at replication foci. Nat. Genet. 25, 269-277. https://doi.org/10.1038/77023
  30. Sakakura, C., Hagiwara, A., Yasuoka, R., Fujita, Y., Nakanishi, M., Masuda, K., Shimomura, K., Nakamura, Y., Inazawa, J., Abe, T., et al. (2001). Tumour-amplified kinase BTAK is amplified and overexpressed in gastric cancers with possible involvement in aneuploid formation. Br. J. Cancer 84, 824-831. https://doi.org/10.1054/bjoc.2000.1684
  31. Sehdev, V., Peng, D., Soutto, M., Washington, M.K., Revetta, F., Ecsedy, J., Zaika, A., Rau, T.T., Schneider-Stock, R., Belkhiri, A., et al. (2012). The aurora kinase A inhibitor MLN8237 enhances cisplatininduced cell death in esophageal adenocarcinoma cells. Mol. Cancer Ther. 11, 763-774. https://doi.org/10.1158/1535-7163.MCT-11-0623
  32. Shechter, D., Dormann, H.L., Allis, C.D., and Hake, S.B. (2007). Extraction, purification and analysis of histones. Nat. Protoc. 2, 1445-1457. https://doi.org/10.1038/nprot.2007.202
  33. Smetana, K., Mikulenkova, D., and Klamova, H. (2011). Heterochromatin density (condensation) during cell differentiation and maturation using the human granulocytic lineage of chronic myeloid leukaemia as a convenient model. Folia Biol. 57, 216-221.
  34. Son, H.J., Kim, J.Y., Hahn, Y., and Seo, S.B. (2012). Negative regulation of JAK2 by H3K9 methyltransferase G9a in leukemia. Mol. Cell. Biol. 32, 3681-3694. https://doi.org/10.1128/MCB.00673-12
  35. Sugarman, J.L., Schonthal, A.H., and Glass, C.K. (1995). Identification of a cell-type-specific and E2F-independent mechanism for repression of cdc2 transcription. Mol. Cell. Biol. 15, 3282-3290. https://doi.org/10.1128/MCB.15.6.3282
  36. Tonelli, R., Sartini, R., Fronza, R., Freccero, F., Franzoni, M., Dongiovanni, D., Ballarini, M., Ferrari, S., D'Apolito, M., Di Cola, G., et al. (2006). G1 cell-cycle arrest and apoptosis by histone deacetylase inhibition in MLL-AF9 acute myeloid leukemia cells is p21 dependent and MLL-AF9 independent. Leukemia 20, 1307-1310. https://doi.org/10.1038/sj.leu.2404221
  37. Valerio, D.G., Xu, H., Chen, C.W., Hoshii, T., Eisold, M.E., Delaney, C., Cusan, M., Deshpande, A.J., Huang, C.H., Lujambio, A., et al. (2017). Histone Acetyltransferase Activity of MOF Is Required for MLL-AF9 Leukemogenesis. Cancer Res. 77, 1753-1762. https://doi.org/10.1158/0008-5472.CAN-16-2374
  38. van Haaften, G., Dalgliesh, G.L., Davies, H., Chen, L., Bignell, G., Greenman, C., Edkins, S., Hardy, C., O'Meara, S., Teague, J., et al. (2009). Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer. Nat. Genet. 41, 521-523. https://doi.org/10.1038/ng.349
  39. Van Hooser, A., Goodrich, D.W., Allis, C.D., Brinkley, B.R., and Mancini, M.A. (1998). Histone H3 phosphorylation is required for the initiation, but not maintenance, of mammalian chromosome condensation. J. Cell Sci. 111 ( Pt 23), 3497-3506.
  40. Venkataraman, S., Alimova, I., Tello, T., Harris, P.S., Knipstein, J.A., Donson, A.M., Foreman, N.K., Liu, A.K., and Vibhakar, R. (2012). Targeting Aurora Kinase A enhances radiation sensitivity of atypical teratoid rhabdoid tumor cells. J. Neurooncol. 107, 517-526. https://doi.org/10.1007/s11060-011-0795-y
  41. Warrell, R.P., Jr. (1999). Arsenicals and inhibitors of histone deacetylase as anticancer therapy. Haematologica 84 Suppl EHA-4, 75-77.
  42. Zhao, W., Li, Q., Ayers, S., Gu, Y., Shi, Z., Zhu, Q., Chen, Y., Wang, H.Y., and Wang, R.F. (2013). Jmjd3 inhibits reprogramming by upregulating expression of INK4a/Arf and targeting PHF20 for ubiquitination. Cell 152, 1037-1050. https://doi.org/10.1016/j.cell.2013.02.006
  43. Zuber, J., Shi, J., Wang, E., Rappaport, A.R., Herrmann, H., Sison, E.A., Magoon, D., Qi, J., Blatt, K., Wunderlich, M., et al. (2011). RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature 478, 524-528. https://doi.org/10.1038/nature10334

Cited by

  1. JMJD3 in the regulation of human diseases vol.10, pp.12, 2018, https://doi.org/10.1007/s13238-019-0653-9
  2. Proteosomal degradation of NSD2 by BRCA1 promotes leukemia cell differentiation vol.3, pp.1, 2018, https://doi.org/10.1038/s42003-020-01186-8
  3. Negative Regulation of Erythroid Differentiation via the CBX8-TRIM28 Axis vol.44, pp.7, 2018, https://doi.org/10.14348/molcells.2021.0012